Resolution of CMV Infection in the Bowel on Vedolizumab Therapy

Rawa-Golebiewska Anna; Lenarcik Malgorzata; Zagorowicz Edyta

首页> 外文期刊>Journal of Crohn’s & colitis >Resolution of CMV Infection in the Bowel on Vedolizumab Therapy

【24h】

Resolution of CMV Infection in the Bowel on Vedolizumab Therapy

机译：Vedolizumab疗法肠道中CMV感染的分辨率

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of Crohn’s & colitis》 |2019年第9期|共2页
作者
Rawa-Golebiewska Anna; Lenarcik Malgorzata; Zagorowicz Edyta;
展开▼
作者单位

Maria Sklodowska Curie Mem Canc Ctr &

Inst Oncol Dept Oncol Gastroenterol Warsaw Poland;

Maria Sklodowska Curie Mem Canc Ctr &

Inst Oncol Dept Oncol Gastroenterol Warsaw Poland;

Maria Sklodowska Curie Mem Canc Ctr &

Inst Oncol Dept Oncol Gastroenterol Warsaw Poland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类杆菌传染病;
关键词

相似文献

外文文献
中文文献
专利

1. Comment on: 'Resolution of CMV Infection in the Bowel on Vedolizumab Therapy' [J] . Hommel C., Pillet S., Rahier J. -F. Journal of Crohn’s & colitis . 2020,第1期

机译：评论：'肠肠肠道CMV感染的分辨率'
2. Risk of post‐operative surgical site infections after vedolizumab vs anti‐tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease [J] . Park K. T., Sceats L., Dehghan M., Alimentary pharmacology & therapeutics. . 2018,第3期

机译：Vedolizumab后术后手术部位感染的风险对抗肿瘤坏死因子治疗：炎症性肠病中的倾向评分匹配分析
3. Kinetic of the CMV CMV ‐specific T‐cell immune response and CMV CMV infection in CMV CMV ‐seropositive kidney transplant recipients receiving rabbit anti‐thymocyte globulin induction therapy: A pilot study [J] . Martín‐Gandul Cecilia, Pérez‐Romero Pilar, Mena‐Romo Damián, Transplant infectious disease: an official journal of the Transplantation Society . 2018,第3期

机译：CMV CMV-特异性T细胞免疫反应和CMV CMV -Seroposigive肾移植受体接受兔抗胸腺细胞球蛋白诱导治疗的CMV CMV-CMV感染：试验研究
4. Effect of ageing and CMV infection on CD8 T cell subsets [C] . Pita-Lopez M L., Gayoso I, DelaRosa O., European Congress of Immunology . 2009

机译：老化和CMV感染对CD8 T细胞亚群的影响
5. The host resistance locus Cmv1/Ly49h regulates global gene expression in spleen DX5+ NK cells in response to murine cytomegalovirus infection. [D] . Kim, Kwangsin. 2006

机译：宿主抗性基因座Cmv1 / Ly49h调节脾脏DX5 + NK细胞中的整体基因表达，以响应鼠巨细胞病毒感染。
6. Risk of Postoperative Surgical Site Infections after Vedolizumab versus Anti-Tumor Necrosis Factor Therapy: A Propensity-Score Matching Analysis in Inflammatory Bowel Disease [O] . KT Park, Lindsay Sceats, Melody Dehghan, -1

机译：维多珠单抗与抗肿瘤坏死因子治疗后术后手术部位感染的风险：炎性肠病倾向得分匹配分析
7. P347 Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases [O] . M Attauabi, C Höglund, J Fassov, 2021

机译：P347 vedolizumab作为老年人生物治疗禁忌患者反对抗TNF疗法 - 一个真正的全球全球全国炎症肠疾病患者
8. Development of Antiviral Drugs for Treatment of Cytomegalovirus (CMV) Infections, Particularly in AIDS (Acquired Immuno-Deficiency Syndrome) and Other Immunosuppressed Patients. Annual Report July 1, 1985-June 30, 1986 [R] . Wright, G. E. , Medveczky, P. 1986

机译：用于治疗巨细胞病毒（CmV）感染的抗病毒药物的开发，特别是在艾滋病（获得性免疫缺陷综合症）和其他免疫抑制患者中。年报1985年7月1日至1986年6月30日

Resolution of CMV Infection in the Bowel on Vedolizumab Therapy

著录项

相似文献

相关主题

期刊订阅